biOasis Provides Scientific Updates on Its Transcend Programs - Seite 3

Up to 5% of the injected dose of the MTfp-antibody fusion entered the brain and showed peak transport at 24 hours. Active transport into the brain of between 3-4% continued for more than 12 days. In contrast, the full-length MTf-antibody fusion showed a peak of brain exposure at approximatively 2 hrs, which decreased afterwards, exhibiting a half-life in plasma of 5 days. Importantly, administration of either MTf-antibody or MTfp-antibody fusion or conjugate produced a greater degree of analgesia in the neuropathic pain model when compared to administration of the antibody alone. Analgesia is dependent on the antibody entering the CNS.

Stated CEO Rob Hutchison, "These results with MedImmune are of great importance for biOasis and its licensing business model. We now know that the MTfp amino acid sequence can be provided to a licensee and the licensee will be able to build the sequence into its therapeutics with relative ease and with low manufacturing costs. In addition, the increased half-life observed with the MTfp transport vector results in a much higher exposure of the therapeutic in the brain, a key consideration for our potential licensing partners."

About Transcend

Transcend is biOasis' proprietary platform for the delivery of therapeutics across the BBB to address unmet medical needs in the treatment of metastatic brain cancers as well as neurodegenerative and metabolic diseases. The BBB represents the single greatest challenge in treating neurological disorders. The ability to effectively and selectively breech the BBB offers the opportunity for biOasis to deliver therapeutics into the brain. Transcend was originally based on MTf (melanotransferrin or p97) where the full-length protein was conjugated to therapeutic molecules. Recently biOasis identified a family of peptides within MTf that facilitates receptor-mediated transcytosis. The lead peptide carrier was used in the work reported above.

About biOasis

biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada focused on overcoming the limitations of therapeutic drug delivery across the BBB. The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQX under the symbol "BIOAF" and on the TSX Venture Exchange under the symbol "BTI". For more information about the company please visit www.bioasis.ca.